Adolor Corp.
700 Pennsylvania Drive
Exton,
PA 19341
United States - Map
Phone: 484-595-1500
Fax: 484-595-1515
Web Site: http://www.adolor.com
| Adolor Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of prescription pain management products. Its product includes ENTEREG (alvimopan), a small molecule peripherally-acting mu-opioid receptor antagonist designed to block the adverse side effects of opioid analgesics on the gastrointestinal tract, as well as for the management of postoperative ileus following bowel resection surgery that causes significant discomfort for patients. The companys product candidates in various stages of clinical and preclinical development include two novel delta opioid receptor agonists that are in mid-stage clinical development in collaboration with Pfizer Inc. for chronic pain; a mu opioid receptor antagonist entering development for chronic OBD; and various opioid and non-opioid discovery programs. Adolor Corporation was founded in 1993 and is headquartered in Exton, Pennsylvania. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Michael R. Dougherty , 51
Chief Exec. Officer, Pres, Director and Member of Secondary Committee on Options |
$
575.00K |
$
0 | Mr. Stephen W. Webster , 47
Chief Financial Officer, Principal Accounting Officer and Sr. VP of Fin. |
$
219.00K |
$
0 | Dr. Eliseo Oreste Salinas M.D., M.Sc, 53
Chief Medical Officer and Sr. VP of R&D |
$
366.00K |
$
0 | Mr. John M. Limongelli Esq., 39
Sr. VP, Sec. and Gen. Counsel |
$
140.00K |
$
0 | Dr. David Jackson M.D., 61
Corp. Medical Advisor |
$
455.00K |
$
0 |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
1.48% Nasdaq 
Profile
